J&J sees Q2 sales rise
pharmafile | July 17, 2013 | News story | Sales and Marketing | Elan, J&J, JJ, Q2, Synthes, sales
Johnson & Johnson saw overall sales rise 8.5% year-on-year in the second quarter of 2013, with the US healthcare group posting revenues of $17.9 billion for the three months to the end of June.
The rise in turnover was partly due to the gain on the sale of the equity interest in Elan Corporation, but domestic sales were also up 8%, with international sales rising 9% on the same period in 2012.
Pharma performed strongly, with Q2 sales of $7 billion representing an increase of 11.7%, with US sales up 9.1% and overseas sales up 14.1% after a negative currency impact of 2.4 per cent.
These figures included the acquisition of Synthes and were net of the cost of getting rid of the DePuy trauma business, although there is a $0.5 billion cost related to legal, integration and transaction costs associated with both.
“Our strong second-quarter results reflect the progress we’ve made against our near-term priorities of delivering on our financial commitments, restoring a reliable supply of over-the-counter products to consumers, continuing the successful integration of Synthes and building on the momentum in our pharmaceutical business,” said chief executive Alex Gorsky.
It continues the positive story from Q1, when J&J reported a rebound in its OTC brands largely thanks to the re-launch of products that had seen their production restricted or suspended because of quality failures.
The group had a decent second quarter on the regulatory front, with the FDA approving Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis in adults.
The US regulator also granted Breakthrough Therapy Designation for daratumumab for patients with multiple myeloma who have received at least three prior lines of therapy.
J&J also agreed last month to buy privately-held company Aragon Pharmaceuticals, giving it access to Aragon’s lead product candidate, a second generation androgen receptor signalling inhibitor, ARN-509, in Phase II for castration-resistant prostate cancer.
J&J has given shareholders some cheer too, increasing earnings guidance for 2013 to $5.40 – $5.47 per share.
Adam Hill
Related Content
J&J’s Tremfya meets primary and secondary endpoints in UC maintenance study
Johnson & Johnson (J&J) has announced the first data from its phase 3 QUASAR maintenance …
J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer
Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products …
FDA approves J&J’s Opsynvi for PAH treatment
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has …
